Zolpidem
- Generic Name
- Zolpidem
- Brand Names
- Ambien, Edluar, Intermezzo, Tovalt
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21N3O
- CAS Number
- 82626-48-0
- Unique Ingredient Identifier
- 7K383OQI23
- Background
Zolpidem, also known as Ambien, is a hypnotic drug that was initially approved by the FDA in 1992 . Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during s...
- Indication
This drug is indicated for the short-term treatment of insomnia in adults characterized by difficulties with sleep initiation .
- Associated Conditions
- Insomnia
- Associated Therapies
- -
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Midnight Pharma, LLC
- Target Recruit Count
- 709
- Registration Number
- NCT00608985
- Locations
- 🇦🇺
The Woolcock Institute of Medical Research, Glebe, Australia
🇦🇺Australian Clinical Research Organisation, Kippa Ring, Australia
🇦🇺Melbourne Sleep Disorder Centre, Melbourne, Australia
Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 30
- Registration Number
- NCT00602719
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 30
- Registration Number
- NCT00601666
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Insomnia and Daytime Function in Osteoarthritis
- Conditions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 170
- Registration Number
- NCT00530556
Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children
- Conditions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2007-06-29
- Target Recruit Count
- 63
- Registration Number
- NCT00494468
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸National Jewish Medical and Research Center, Denver, Colorado, United States
Disturbed Sleep Model Study.
- Conditions
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT00440323
- Locations
- 🇬🇧
GSK Investigational Site, Guildford, Surrey, United Kingdom
Sleepiness and the Risk of Falling
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 24
- Registration Number
- NCT00383357
- Locations
- 🇺🇸
University of Colorado at Boulder, Boulder, Colorado, United States
Stilnox Treatment in Elderly Patients With Insomnia
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT00359229
STILDEP: Zolpidem in Depressive and Dysthimic Patients
- Conditions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2007-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 120
- Registration Number
- NCT00292734
- Locations
- 🇭🇺
Sanofi-Aventis, Budapest, Hungary
Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo
- Conditions
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT00286936
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.